Alto Neuroscience Releases Phase 2 Topline Data for ALTO-101 and Provides Strategic Pipeline Update

Key Highlights

• Phase 2 proof-of-concept study for ALTO-101 in cognitive impairment associated with schizophrenia (CIAS) did not meet primary statistical endpoints.
• Directional improvements observed in some EEG measures, especially theta-ITC, with near-significant results (p=0.052).
• Modified-release, once-daily oral formulation of ALTO-101 developed with improved tolerability and pharmacokinetics.
• ALTO-207 for treatment-resistant depression remains the company’s top priority; Phase 2b trial initiation expected in first half of 2026.
• Strong financial position: \$275 million in cash, enabling continued advancement of pipeline and operations through key milestones.

Detailed Analysis of ALTO-101 Phase 2 Study

Alto Neuroscience announced topline results from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 for CIAS. The trial did not achieve statistical significance on primary EEG or cognitive endpoints versus placebo. However, the study revealed directional improvements in certain EEG measures, notably a near-significant effect on theta-ITC (effect size d=0.34, p=0.052, n=83). In a pre-specified subgroup of more cognitively impaired patients (n=59), ALTO-101 demonstrated a nominally significant effect on theta-ITC (d=0.44, p=0.03).

The results also indicated that a longer treatment period might reveal greater effects, as improvements were seen from day 5 to day 10 in the trial. Importantly, ALTO-101 showed a favorable tolerability profile, with rates of nausea and vomiting (common side effects for PDE4 inhibitors) comparable to placebo. This suggests that the pharmacokinetic profile of ALTO-101 may address a key barrier that has limited the adoption of PDE4 inhibitors. Notably, high rates of application site skin reactions were observed in both active and placebo groups.

Strategic Pipeline Decisions and Shareholder Impact

Based on these results, Alto Neuroscience will not independently advance ALTO-101 in CIAS. Instead, the company will prioritize its lead program, ALTO-207, and seek partnering opportunities for the modified-release oral formulation of ALTO-101, which has demonstrated improved pharmacokinetics and tolerability. This formulation is protected by a pending patent application and may hold potential across multiple therapeutic areas.

Shareholders should note: The decision to halt independent advancement of ALTO-101 in CIAS and shift focus to ALTO-207 is a key strategic move. These changes could affect the company’s valuation, depending on future partnering success for ALTO-101 and progress with ALTO-207.

ALTO-207: Focused Advancement in Treatment-Resistant Depression

ALTO-207, Alto’s most advanced and differentiated program, is on track to initiate a randomized, double-blind, placebo-controlled Phase 2b trial in 1H 2026. ALTO-207 is a fixed-dose combination of pramipexole (dopamine D3/D2 agonist) and ondansetron (5-HT3 antagonist), designed to achieve higher pramipexole doses by reducing dose-limiting nausea and vomiting. The trial will include about 178 adults with treatment-resistant depression (TRD) who have failed two to five prior treatments.

The mechanism of ALTO-207 is supported by the PAX-D study (University of Oxford, published in The Lancet Psychiatry), which showed a Cohen’s d=0.87 effect size for pramipexole versus placebo at 12 weeks, substantially higher than current approved TRD treatments. Alto’s own Phase 2a trial for ALTO-207 met both primary and secondary endpoints. After a successful FDA meeting in 2025, Alto is positioned to advance ALTO-207 through Phase 3 and a potential NDA submission.

Financial Position and Investor Outlook

Alto Neuroscience enters this period with a strong financial position, holding \$275 million in cash. This capital is expected to be sufficient to fund operations and clinical milestones, including the progression of ALTO-207, and potentially drive value through partnering opportunities for ALTO-101.

The company’s pipeline includes other clinical-stage drug candidates targeting bipolar depression, major depressive disorder, schizophrenia, and additional mental health conditions, all leveraging Alto’s Precision Psychiatry Platform™ for personalized treatment approaches.

Potential Share Price Catalysts

• The failure to meet primary endpoints for ALTO-101 may be perceived negatively, but the pipeline prioritization towards ALTO-207, with robust supporting data and imminent Phase 2b initiation, could offset investor concerns.
• Strategic partnering opportunities for the modified-release ALTO-101 formulation may unlock additional value.
• The company’s strong cash position and diversified pipeline may reassure investors about future growth potential and operational stability.
• Upcoming presentations of study data at future medical conferences may provide further catalysts.

Disclaimer

This article contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on Alto Neuroscience’s expectations and are subject to risks and uncertainties, including clinical trial progress, product candidate development, regulatory approvals, and other factors that may cause actual results to differ materially. Investors should consult Alto’s SEC filings, including its Annual Report and other documents, for risk factors and additional information. The information herein is for informational purposes only and does not constitute investment advice.

View Alto Neuroscience, Inc. Historical chart here